PANAGENE INC. of Daejeon at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers

PANAGENE INC.

54, Techno 10-ro, Yuseong-gu, 34027 Daejeon
Korea, Republic
Telephone +82 42 8619296
Fax +82 42 9369290
serim.lee@panagene.com

Hall map

MEDICA 2018 hall map (Hall 3): stand J60

Fairground map

MEDICA 2018 fairground map: Hall 3

Contact

Morgan Lee

Daejeon, Korea, Republic

Phone
+82-10-4970-6170
+82-42-861-9296

Fax
+82-42-936-9290

Email
order@panagene.com

Seewook Kim

Daejeon, Korea, Republic

Phone
+82-10-3422-9150
+82-42-861-9296

Fax
+82-42-936-9290

Email
seewook.kim@panagene.com

Our range of products

Product categories

  • 03  Diagnostics
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.04  Other molecular diagnostics testing

Other molecular diagnostics testing

Our products

Product category: Other molecular diagnostics testing

PANA RealTyper™ HPV Kit

HPV
According to the WHO report (2008), human papillomavirus (HPV) causes virtually 100% of cases of cervical cancers. There are more than 100 genotypes of HPV reported currently, and HPV consists of double helix circular DNA with ca. 7,900 bps. Compared to the traditional Pap smear test, HPV genotyping has several advantages; 1) high accuracy of determining existence of HPV viruses, 2) genotyping of the HPV viruses, 3) early diagnosis, 4) identifying patients harboring HPV with high risk type, and 5) contribution to prevention and therapy of cervical cancers in the end.
PANA RealTyper™ HPV kit is an in vitro diagnostic reagent for genotyping of human papilloma virus (HPV) using peptide nucleic acid (PNA) probes. This kit is an amplified DNA test for the qualitative detection of a total of 40 HPV genotypes in a real-time PCR (polymerase chain reaction) system. This kit provides genotyping information of 20 high-risk and 2 low-risk types using melting temperature (Tm) analysis. Furthermore, this kit also detects 18 other genotypes (without genotyping) in DNA samples from clinical specimens.

More Less

Product category: Other molecular diagnostics testing

PANAMutyper™ R EGFR Kit

KRAS
KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, biliary tract cancer and thyroid cancer. The existence of KRAS mutations is often related with a prognostic marker to drug response. For example, KRAS mutation is considered a strong prognostic marker for drug response of tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related with drug response to Cetuximab (Erbitux) or Panitumumab (Vectibix) that is used for colon cancer therapy. Therefore, examination of KRAS mutation is needed to determine drug resistance of patients with colorectal or lung cancers and will be helpful for cancer therapies.

More Less

About us

Company details

We will always make our best efforts to develop innovative platform technologies and to be a global leader in the field of molecular diagnostics.

Based on the advantage of PNA material and our accumulated knowledge, we have developed various innovative platform technologies on molecular diagnostics covering multiplexing, mutated gene specific amplification, SNP discrimination and so on. To meet rapidly changing diagnostic market needs, our efforts for innovation will continue.

We have been developing and launching accurate and convenient in vitro diagnostic products consistently. We exercise strict quality management policy and make efforts to meet global standards and appropriate regulations for our IVD products. We believe that results of our efforts to produce IVD products will greatly contribute for helping human healthcare in the future.

More Less